J 2014

Ethamsylate (Dicynone®) Interference in Determination of Serum Creatinine, Uric Acid, Triglycerides, and Cholesterol in Assays Involving the Trinder Reaction; In Vivo and In Vitro

DASTYCH, Milan, Ondřej WIEWIORKA a Miroslava BEŇOVSKÁ

Základní údaje

Originální název

Ethamsylate (Dicynone®) Interference in Determination of Serum Creatinine, Uric Acid, Triglycerides, and Cholesterol in Assays Involving the Trinder Reaction; In Vivo and In Vitro

Autoři

DASTYCH, Milan (203 Česká republika, garant, domácí), Ondřej WIEWIORKA (203 Česká republika) a Miroslava BEŇOVSKÁ (203 Česká republika, domácí)

Vydání

Clinical Laboratory, Heidelberg, Clinical Laboratory Publications, 2014, 1433-6510

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

10600 1.6 Biological sciences

Stát vydavatele

Německo

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.129

Kód RIV

RIV/00216224:14110/14:00076245

Organizační jednotka

Lékařská fakulta

DOI

UT WoS

000342857800015

Klíčová slova anglicky

trinder reaction; interference; ethamsylate

Štítky

Příznaky

Mezinárodní význam, Recenzováno
Změněno: 19. 10. 2015 15:13, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Background: The aim of our research was the quantification of interfering properties of the haemostatic drug Dicynone® (ethamsylate) in serum creatinine, uric acid, cholesterol, and triglyceride assays using the Trinder reaction. Methods: Blood from patients was collected before and 15 minutes after administration of 500 mg Dicynone® dose i.v. and the above mentioned analytes were quantified using Roche assays (Cobas 8000). In our in vitro experiment, we measured concentrations of the analytes in pooled serum aliquots with final concentrations of Dicynone® additions 0, 30, 60, 150, and 300 mg/L. Aliquots with 60 mg/L Dicynone® were also measured at 2, 6, and 8 hours after initial measurement when stored in 22°C and 4°C for comparison. Results: Concentrations of the measured analytes in samples from patients administered with a 500 mg dose of Dicynone® were lower in all cases (n = 10) when compared to values in samples taken immediately before treatment. The in vitro samples showed that considerable negative interference occurred even with the low concentrations of Dicynone® additions (30 and 60 mg/L), showing the strongest negative interference in creatinine values, followed by uric acid, triglycerides, and cholesterol. Using in vitro samples, we showed strong time and temperature dependence on Dicynone® interference. Conclusions: We found and proved significant negative interference of the drug Dicynone® (ethamsylate) in the clinical analysis of blood using in vivo and in vitro experiments. Furthermore, we observed a change of this effect in serum matrix over time and at different storage temperatures.